44 results about "Lymphocyte activation" patented technology

The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.

The present invention relates to regulation of lymphocyte activation. In particular, it relates to compositions and methods for regulating lymphocyte activation by selectively binding multiple cell surface antigens expressed by the same lymphocyte.

The invention discloses an application of anemoside B4 used as an immunomodulator to drugs for treating acute inflammations. The anti-inflammatory effect of the anemoside B4 is directly produced through inhibition of lymphocyte activation and inflammatory factor secretion. The application of the anemoside B4 used as the immunomodulator to the drugs for treating acute inflammations is disclosed for the first time, and the anemoside B4 belongs to a purely natural preparation, is safe, reliable and free of side effects and has potential development value for the drugs for treating acute inflammations.

An antibody or antibody fragment directed against the CD28 receptor which blocks the interaction between B7-1 or B7-2 and CD28. Methods for blocking activation via CD28, including CD28-dependent lymphocyte activation.

The invention provides a preparation method of bispecific chimeric antigen receptor gene modified natural killer cells, comprising the features: constructing a bispecific chimeric antigen receptor gene containing specific-binding signaling lymphocyte activation molecule family member 7 and fibronectin mutants, recombining the bispecific chimeric antigen receptor gene to a viral vector, transfecting with human natural killer cells, and highly expressing the bispecific chimeric antigen receptor gene, thus specifically binding tumor cells that express the signaling lymphocyte activation molecule family member 7 and fibronectin mutants, inhibiting expression of natural killer cell inhibitory receptors, and preventing immune escape of tumor cells; meanwhile, activating a first signal and a co-stimulatory signal to trigger toxic activity of the tumor cells, and great anti-tumor killing toxicity is shown in in-vivo and in-vitro experiments; the invention also provides a kit for the preparation of autologous natural killer cells through the above method, and with the kit, it is possible to highly express the bispecific chimeric antigen receptor gene and trigger great anti-tumor effect.

The present invention discloses 3-deoxyflavonoid compounds and methods for inhibiting T cell activity and treating diseases and disorders (eg, autoimmune diseases, inflammatory diseases, diabetes, ALS, MS, rheumatoid arthritis, etc.). In some cases, the potency and/or duration of action of luteolin and/or other 3-deoxyflavonoid compounds can be increased by administering these compounds together with rutin, rutin analogs, and/or rutin derivatives. Furthermore, in some cases, first-pass metabolism of luteolin or other 3-deoxyflavonoid compounds can be avoided by administering these compounds parenterally (eg, sublingually, bucally, intranasally, injection, etc.).

The invention provides a kit for detecting human regulatory T cell subtypes and a detection method and belongs to the technical field of cell subtype detection. The provided kit comprises components as follows: a blood diluent, a mononuclear cell separation medium, a cell culture fluid, a lymphocyte activation solution, dead cell removal dyes, an FcR blocking agent, a fluorescence labeled antibodyresisting human cell surface labeling molecules, a fluorescence labeled antibody resisting human intracellular molecules, a PBS buffer solution, lipopolysaccharide, a washing buffer solution, a celldyeing buffer solution, a cell fixing solution and a permeable membrane lotion. During detection, firstly, mononuclear cells in whole blood are separated, then, mononuclear cells of human peripheral blood are stimulated, finally, a fluorescent antibody is stained, and the regulatory T cell subtypes can be detected. By use of the kit and the detection method, 2-6 regulatory T cell subtypes can be simply and rapidly distinguished.

Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion.

The invention discloses a method for determining the biological activity of an LAG3 (Lymphocyte Activation Gene-3) protein binding molecule. The method comprises the step of detecting the activity ofan anti-human LAG3 antibody by a co-expression NFAT (Nuclear Factor of Activated T cells) reporting element and Jurkat cells of human LAG3 protein under the condition of coexistence of SED and Raji cells. The method provided by the invention can be used for rapidly and accurately detecting the activity of the molecule bound with human LAG3 protein.

The invention relates to a novel nano gene drug capable of stimulating lymphocyte activation and a preparation method thereof. The invention discloses a fusion gene; and a mouse beta-2 microglobulin signal peptide is introduced from the upstream of the fusion gene dsNKG2D-IL-21 gene to obtain the fusion gene ATG-sig-dsNKG2D-IL-21. The invention also discloses a fusion gene expression carrier pcDNA3.1-sig-dsNKg2D-IL-21. The invention also discloses a nano gene vaccine drug which is formed by encapsulating the pcDNA3.1-sig-dsNKg2D-IL-21 fusion protein expression vector with chitosan. The invention also discloses a preparation method of a nano gene vaccine. The nano drug is used for carrying a nano gel of the recombinant dsNKG2D-IL-21 gene vector capable of stimulating lymphocyte activation and in-vivo targeted distribution, and is hopeful to become a drug for resisting tumors and infectious diseases.

A method for classifying patients at risk for cardiovascular disease, other chronic inflammatory diseases, cardiovascular and/or non-cardiovascular morbidity and mortality based on a risk assessment for lymphocyte activation gene 3 (LAG3) protein deficiency, and for mediating the risk using recombinant lymphocyte activation gene-3 or LAG3 mimetic as a companion therapeutic alone or in combination with a statin and/or an anti-hyperlipidemic drug. The risk assessment is two-prong, beginning with a qualitative determination whether a subject has or is predisposed to abnormal expression of inflammasomes, heightened risk for inflammation and/or to dysfunctional HDL, followed by a quantitative assay or genetic screen for a polymorphism that occurs in the coding sequence of the LAG3 gene. Given positive indication, recombinant LAG3 and/or LAG3 mimetic is used alone or in combination with the therapeutic use of a cholesterol mediating drug for treatment.

The invention discloses an antibody resisting a lymphocyte activation gene 3 (LAG-3). The antibody has a unique CDR region and a variable region sequence, has highly specific binding activity with a target antigen LAG-3, and can effectively block binding of the LAG-3 and an MHCII molecule and binding of the LAG-3 and an FGL1 molecule. The invention also provides a composition of the antibody and an anti-PD-1 antibody, and the antibody and the anti-PD-1 antibody show an excellent synergistic effect of inhibiting tumor growth through combination. The invention further provides application of theantibody in preparation of a drug for treating, preventing and diagnosing tumor or/and infectious diseases.

The invention discloses a CD3/CD28/DLL4 magnetic bead. The surface of the magnetic bead is coupled with an anti-human CD3 antibody, an anti-human CD28 antibody and a recombinant human DLL4 protein. The invention also discloses a preparation method and application of the CD3/CD28/DLL4 magnetic bead. When the CD3/CD28/DLL4 magnetic bead amplifies T lymphocytes, TCR on the surfaces of the T lymphocytes can be combined with anti-CD3 antibody cross-linked on the surfaces of the magnetic bead, and a first signal for activating the T lymphocytes is provided; cD28 on the surface of the T lymphocytes can be combined with the anti-CD28 antibody cross-linked on the surface of the magnetic bead to provide a second signal for activating the T lymphocytes; and the DLL4 can effectively promote the differentiation of CD4 + T cells into Th1 effector cells and promote the differentiation of CD8 + T cells into cytotoxic CD8 + T effector cells. The proportion of CD8 + T cells in the T cell mixture generated by CD3/CD28/DLL4 magnetic bead culture exceeds that of the T cell mixture obtained by traditional CD3/CD28 magnetic bead amplification, and the generated CD8 + T cells can secrete higher-level killing factors when encountering antigen stimulation.

The invention relates to a gene modification non-human animal of a humanized gene, in particular to a gene modification rodent, especially a gene modification mouse. The invention particularly relatesto a construction method for a humanized LAG-3 (lymphocyte activation gene 3) modification animal model, and application of the humanized LAG-3gene modification animal model in the field of biological medicines.

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Lymphocyte-Activation Gene 3 (LAG3) antagonist, and the use of the combination therapies for the treatment of non-microsatellite instability-high (non-MSI-H) or proficient mismatch repair (pMMR) colorectal cancer.

Methods for measuring the function of lymphocytes and their responses to mitogens or specific antigens, with or without co-stimulatory agents, is provided. The methods are suitable for measurement of the responses of lymphoid cells when they are a subpopulation of cells, and also for measuring the function of specific subsets of lymphoid cells, each subpopulation or subset of a subpopulation having characteristic determinants on their cell surface. The invention also relates to test kits used in performing such methods. The methods of the invention facilitate screening of complex biological fluids, such as whole blood, by means of incubating a sample of the fluid with a mitogen or antigen, with or without co-stimulatory elements, separating the selected subset of interest, e.g., via affinity separation, and detecting the presence of an internal cellular component, advantageously ATP, that is increased as a result of the response.